WINTON GROUP Ltd Grows Stake in Arcus Biosciences, Inc. (NYSE:RCUS)

WINTON GROUP Ltd raised its stake in shares of Arcus Biosciences, Inc. (NYSE:RCUS) by 5.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 72,310 shares of the company’s stock after purchasing an additional 3,730 shares during the period. WINTON GROUP Ltd owned 0.08% of Arcus Biosciences worth $1,077,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also modified their holdings of the stock. R Squared Ltd purchased a new stake in Arcus Biosciences during the 4th quarter valued at $26,000. Point72 Hong Kong Ltd purchased a new stake in shares of Arcus Biosciences in the third quarter valued at $47,000. US Bancorp DE raised its stake in shares of Arcus Biosciences by 2,432.0% in the fourth quarter. US Bancorp DE now owns 6,887 shares of the company’s stock valued at $103,000 after acquiring an additional 6,615 shares during the period. Quest Partners LLC lifted its holdings in shares of Arcus Biosciences by 40,904.3% in the 3rd quarter. Quest Partners LLC now owns 9,431 shares of the company’s stock worth $144,000 after acquiring an additional 9,408 shares during the last quarter. Finally, AXQ Capital LP purchased a new position in shares of Arcus Biosciences during the 4th quarter worth about $160,000. 92.89% of the stock is owned by institutional investors.

Insider Activity at Arcus Biosciences

In other Arcus Biosciences news, CFO Robert C. Goeltz II sold 3,594 shares of the stock in a transaction dated Tuesday, December 31st. The shares were sold at an average price of $15.00, for a total transaction of $53,910.00. Following the completion of the sale, the chief financial officer now directly owns 60,138 shares of the company’s stock, valued at approximately $902,070. This represents a 5.64 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Terry J. Rosen purchased 19,800 shares of the stock in a transaction dated Thursday, February 27th. The stock was purchased at an average price of $10.18 per share, for a total transaction of $201,564.00. Following the completion of the acquisition, the chief executive officer now directly owns 2,554,160 shares in the company, valued at approximately $26,001,348.80. This represents a 0.78 % increase in their position. The disclosure for this purchase can be found here. 12.30% of the stock is currently owned by corporate insiders.

Arcus Biosciences Price Performance

Shares of RCUS stock opened at $8.17 on Friday. Arcus Biosciences, Inc. has a twelve month low of $8.02 and a twelve month high of $18.98. The company has a current ratio of 5.24, a quick ratio of 5.24 and a debt-to-equity ratio of 0.08. The stock has a fifty day simple moving average of $11.11 and a two-hundred day simple moving average of $14.35. The stock has a market capitalization of $858.45 million, a price-to-earnings ratio of -2.59 and a beta of 1.36.

Arcus Biosciences (NYSE:RCUS) last released its quarterly earnings data on Tuesday, February 25th. The company reported ($1.03) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.17) by $0.14. Arcus Biosciences had a negative net margin of 102.66% and a negative return on equity of 45.59%. The company had revenue of $36.00 million during the quarter, compared to analyst estimates of $29.38 million. On average, analysts predict that Arcus Biosciences, Inc. will post -3.15 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently weighed in on RCUS shares. Bank of America reduced their price objective on shares of Arcus Biosciences from $22.00 to $17.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 19th. Morgan Stanley reduced their price target on Arcus Biosciences from $36.00 to $25.00 and set an “overweight” rating on the stock in a report on Tuesday, February 18th. Finally, HC Wainwright upgraded Arcus Biosciences from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $18.00 to $24.00 in a report on Wednesday, February 26th. One research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Arcus Biosciences has a consensus rating of “Buy” and a consensus target price of $30.25.

Arcus Biosciences Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.